Adamas Pharma (ADMS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2021 | 06-2021 | 03-2021 | 12-2020 | 09-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 78,623 | 88,797 | 124,831 | 71,660 | 50,803 |
| Marketable Securities | 4,475 | 2,573 | N/A | 11,705 | 41,674 |
| Receivables | 10,046 | 10,103 | 12,421 | 8,042 | 7,648 |
| Inventories | 8,680 | 7,788 | 7,536 | 7,294 | 6,854 |
| TOTAL | $108,002 | $115,656 | $158,104 | $111,736 | $123,941 |
| Non-Current Assets | |||||
| PPE Net | 1,309 | 1,407 | 1,488 | 1,598 | 1,789 |
| Investments And Advances | 27,991 | 26,886 | 2,605 | 0 | 0 |
| Intangibles | 687 | 715 | 742 | 0 | 0 |
| Other Non-Current Assets | 5,988 | 5,980 | 6,308 | 6,695 | 7,071 |
| TOTAL | $35,975 | $34,988 | $11,143 | $8,293 | $8,860 |
| Total Assets | $143,977 | $150,644 | $169,247 | $120,029 | $132,801 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 4,554 | 4,167 | 3,580 | 3,657 | 3,232 |
| Accounts payable and accrued liabilities | 4,208 | 2,466 | 2,770 | 2,144 | 4,711 |
| Accrued Expenses | 12,963 | 13,105 | 20,867 | 27,164 | 14,142 |
| Other current liabilities | 2,118 | 2,086 | 1,959 | 1,902 | 9,401 |
| TOTAL | $23,843 | $21,824 | $29,176 | $34,867 | $31,486 |
| Non-Current Liabilities | |||||
| Long Term Debt | 124,483 | 125,541 | 126,159 | 126,307 | 126,573 |
| Other Non-Current Liabilities | 17,257 | 7,312 | 7,975 | 8,831 | 9,360 |
| TOTAL | $141,740 | $132,853 | $134,134 | $135,138 | $135,933 |
| Total Liabilities | $165,583 | $154,677 | $163,310 | $170,005 | $167,419 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 45,787 | 45,596 | 45,408 | 30,568 | 28,521 |
| Common Shares | 50 | 50 | 50 | 34 | 33 |
| Retained earnings | -549,722 | -530,204 | -517,860 | -505,287 | -487,014 |
| Other shareholders' equity | 13 | 6 | -1 | 0 | 32 |
| TOTAL | $-21,606 | $-4,033 | $5,937 | $-49,976 | $-34,618 |
| Total Liabilities And Equity | $143,977 | $150,644 | $169,247 | $120,029 | $132,801 |